SCHEMBL18115261

SCHEMBL18115261

Cc1cccc(C=NNc2cc(N3CCOCC3)nc(-c3cccc(O)c3)n2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.70
MAPT P10636 5/20 0.70
KDM4E B2RXH2 5/20 0.70
HPGD P15428 1/20 0.70
SENP7 Q9BQF6 3/20 0.67
SENP6 Q9GZR1 3/20 0.67
ALDH1A1 P00352 1/20 0.67
PIKFYVE Q9Y2I7 3/20 0.57
FES P07332 1/20 0.57
FER P16591 1/20 0.57
TYK2 P29597 1/20 0.57
FRK P42685 1/20 0.57
SYK P43405 1/20 0.57
CAMK1D Q8IU85 1/20 0.57
IRAK4 Q9NWZ3 1/20 0.57
PIK3CA P42336 7/20 0.56
PIK3CB P42338 4/20 0.56
PIK3CG P48736 4/20 0.56
PIK3CD O00329 2/20 0.56
HDAC8 Q9BY41 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18115258 1.00 LMNA (0.70) LMNAMAPTKDM4EHPGDSENP7
SCHEMBL428572 0.91 KDM4E (0.75) LMNAMAPTKDM4EHPGDSENP7
SCHEMBL428571 0.91 KDM4E (0.75) LMNAMAPTKDM4EHPGDSENP7
SCHEMBL18115336 0.86 KDM4E (0.66) LMNAMAPTKDM4EHPGDSENP7
SCHEMBL18121498 0.86 KDM4E (0.66) LMNAMAPTKDM4EHPGDSENP7
SCHEMBL18618039 0.83 KDM4E (0.64) LMNAMAPTKDM4EHPGDSENP7
SCHEMBL18330253 0.83 MAPT (1.00) LMNAMAPTKDM4EHPGDSENP7
SCHEMBL4143852 0.81 PIK3CA (0.57) MAPTPIK3CAPIK3CBPIK3CGPIK3CD
SCHEMBL429035 0.81 MAPT (0.77) LMNAMAPTKDM4EHPGDSENP7
SCHEMBL429036 0.81 MAPT (0.77) LMNAMAPTKDM4EHPGDSENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180271873-A1 METHODS FOR TREATING VIRAL INFECTIONS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH 2018-09-27 US disclosed
WO-2016161176-A1 METHODS FOR TREATING VIRAL INFECTIONS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2016-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180271873-A1 METHODS FOR TREATING VIRAL INFECTIONS HAVCR2, CCL11, EIF2AK2 LMNA 2400/4885MAPT 3102/4885KDM4E 4324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.